

Speakers



Nikolaus Ferstl
Facility Engineering Services



Dr Andreas Flückiger
Formerly F. Hoffmann La-Roche



Dr Markus Keller
Fraunhofer Institute for Manufacturing Engineering and Automation (IPA)



Dr Jean Denis Mallet
Former Head of the French Pharmaceutical Inspection Dpt. AFSSAPS, France



Robert G. Schwarz
GXP TrainCon, Vienna

Cross Contamination Control

Implementation of a Cross Contamination Control Strategy



Live Online Conference on 17/18 March 2026



Highlights

- Regulatory Requirements: Contamination Control Strategy & Cross Contamination
- Sources of Cross Contamination
- Containment Solutions – Avoiding Exposure – Minimizing Cross Contamination
- Segregation of Material & Processes
- Cross Contamination through poor Organisation
- Cross Contamination through poor HVAC Design
- Cross Contamination through poor Equipment Design
- GMP Inspector's/Auditor's View on Cross Contamination
- Cleaning & Cleaning Validation
- Relevant Documentation: CCS, HBEL, QRM

Objective

This GMP training aims at unveiling possible risks of cross contamination during the production process of pharmaceutical products and APIs. This is especially important for patients' safety, product quality and to be in compliance with chapters 3 and 5 of the EU GMP regulation. The prevention of cross contamination has to be documented accordingly, taking into consideration QRM principles according to ICH-Q9.

You will learn

- how to detect possible risks
- how to avoid cross contamination
- how to prove the avoidance of cross contamination
- how to document a regulatory compliant strategy

Background

Cross Contamination is one of the highest risks for patients using pharmaceutical products. Not only the presence of small amounts of antibiotics or other highly potent compounds in medicinal products can cause severe damage, but also carryover of one product into another pharmaceutical product is of high risk to the patient. According to the Medicines & Healthcare Products Regulatory Agency in the United Kingdom for example, product contamination is the second to third highest reason for recalls in the UK in recent years.

The EU commission already reacted on that in 2015 by updating the chapters 3 (premises & equipment) and 5 (production) with the focus on minimizing the risk of cross contamination. Already three years before a new EMA Guide on setting health-based exposure limits was published. This new guide has massive impact on the dedication of facilities and also on the calculation of limits for cleaning validation. Limits for the maximum carryover now have to be calculated by considering the toxicological/pharmacological properties of each single product, answering the question: how much cross contamination is allowed. The latest document addressing cross contamination is the revised EU GMP Annex 1. It contains several paragraphs dealing with cross contamination and contamination in general which includes a risk-based Contamination Control Strategy (CCS) aligned with Quality Risk Management principles according to ICH Q9.

Reasons for cross contamination can be manifold and caused by technical as well as organisational deficiencies. Insufficient cleaning of equipment, poor facility design or inappropriate design of the HVAC system may be reasons as well as contamination via personnel or primary packing material. But also, the design of the production process itself can be the cause for cross contamination, for example due to open product handling during transfer or sampling operations in shared plants without adequate measures.

It is therefore extremely important to mitigate the risk of cross contamination, starting already at the design phase of processes and equipment. In addition, it is essential to understand how contamination risks can be detected.

Some measures include quality oversight walks in production areas or reviewing the documents (SOPs, technical drawings, etc.) already during process development, design qualification and additionally on a regular basis which has to be predefined.

This mitigation of cross contamination risks should be included and regularly reviewed – and updated if required – as part of the contamination control strategy (CCS) which has to be documented accordingly.

Target Audience

This training is aimed at production, QA and engineering departments of pharmaceutical companies to maintain product quality and patient safety in a regulatory compliant production life cycle. Suppliers for the pharmaceutical industry are also addressed in order to better understand the requirements of their customers.

Moderator

Robert G. Schwarz

Programme

Regulatory Requirements: Contamination Control Strategy & Cross Contamination

- The view of EMA
- The view of US-FDA
- Shared facilities regulations
- Contamination and sterile products

Sources of Contamination – Modes of Cross Contamination – Segregation

- Do different sources mean different impact?
- Where cross contamination could occur and different likelihoods
- Is segregation a no brainer?
- Cross contamination in Biotech

Containment Solutions – Avoiding Exposure – Minimizing Cross Contamination

- Exposure and how to determine it
- Equipment and containment concepts
 - Closed product handling
 - Sampling
 - Material transfer
- The PDE/ADE concept: how much contamination is allowed?
- Avoiding cross contamination
 - Airborne contamination
 - Contamination of surfaces
- Containment verification

Cross Contamination through poor Organisation

- Organisational points to consider
- The human factor
- The importance of training and motivation

Cross Contamination through poor HVAC Design

- Airborne particles
- Pressure / hygienic zones – maintaining over pressure
- The clean corridor concept
- Simulation and visualisation of air flow
- Classification of ventilation systems
- Concepts for HVAC systems
- Components of AHUs (filters, Duct work, etc...)
- Classification and change of filters
- Control and monitoring strategies

Cross Contamination through poor Equipment Design

- Cleanability of equipment as the key to avoiding cross contamination
- In-line cleanability? – Cleanability for parts that are disassembled?
- Importance of drainability (cross contamination by product and detergent residues)
- Gap-free and dead-space-free design of system components
 - Components (connections, valves, pumps, sensors)
 - Mixing and preparation vessels, bioreactors
- Cross contamination due to lack of technical support
 - Deterioration of surface quality
 - Wear of static and dynamic seals

Cleaning & Cleaning Validation

- Poor cleaning – main reason for cross contamination
- Dealing with multipurpose strategies in cross contamination control
- Cross Contamination – main focus of cleaning validation

Cross Contamination – View of an GMP Inspector / Auditor

- Differentiation between “cross contamination” and “mixup”
- How is the cross contamination concept addressed in the main GMP guides (EU, FDA, WHO, etc.)?
- How a GMP inspector starts to identify cross contamination risks?
- Is cross contamination only linked to cleaning validation for an inspector?
- Some ‘historical’ cases of cross contamination
- What would you do in the event of possible cross contamination of a product?

Documentation: CCS, HBEL assessment, QRM

- Cross contamination control and CCS
- HBEL – from the environmental risk to patient’s risk
- Cross contamination control – it is all about QRM

Speakers



Nikolaus Ferstl
Facility Engineering Services

Nikolaus Ferstl has a bachelor degree in mechanical engineering. He has been working for M&W (former LSMW), for example as Senior Project Manager and as deputy head of the subsidiary in Vienna. From 2009 to 2024, he was Technical Director of the University Hospital Regensburg and a freelance consultant for building and cleanroom technology. Today, he is Managing Director of the Facility Engineering Services GmbH.



Dr Andreas Flückiger
Formerly F. Hoffmann La-Roche

An occupational physician by training, Andreas Flückiger was the head of the occupational health services of the Roche Group for 32 years. Now retired from this position, he continues to be active as a consultant in occupational and GMP toxicology as well as process containment in the pharmaceutical industry. He is still engaged in various international organisations and in working groups of the ISPE and ASTM.



Dr Markus Keller
Fraunhofer Institute for Manufacturing Engineering and Automation (IPA)

Dr Markus Keller is a biologist and project manager at the Fraunhofer Institute for Manufacturing Engineering and Automation (IPA), Department of Cleanroom and Microproduction. His area of expertise includes the qualification of plants with regard to their cleanroom suitability.



Dr Jean-Denis Mallet
Former head of the French Inspection
Department AFSSAPS, Exyte-Pharmaplan

Jean-Denis Mallet is a pharmacist. He was previously the Head of the Pharmaceutical and Cosmetics Inspection Department at the French Health Products Regulatory Agency. He also used to work in or with the pharmaceutical industry at various positions including QA, Production Management and Engineering. He has also been auditor of the International Red Cross. Now he works for Exyte-Pharmaplan.



Robert G. Schwarz, GXP TrainCon, Austria

Robert Schwarz, graduate in “Bioprocess Engineering” and “Biotechnological Quality Management”, was responsible for environmental monitoring as well as validation of decontamination systems at Baxter (now Shire). Since 2010 he is working as a lecturer in the field of biotechnology with a focus on validation/qualification, aseptic process methods and cleanroom technology at the University of Applied Sciences Vienna.



Live Online Training: Cross Contamination Control
17/18 March 2026

If the bill-to-address deviates from the specifications on the right, please fill out here:

CONCEPT HEIDELBERG
P.O. Box 101764
Fax +49 (0) 62 21/84 44 34

D-69007 Heidelberg
GERMANY

Title, first name, surname

Department

Company

Important: Please indicate your company's VAT ID Number

Purchase Order Number, if applicable

City

ZIP Code

Country

Phone / Fax

E-Mail (Please fill in)

General terms and conditions

If you cannot attend the conference you have two options:

1. We are happy to welcome a substitute colleague at any time.
2. If you have to cancel entirely we must charge the following processing fees:
 - Cancellation until 4 weeks prior to the conference 10 %
 - Cancellation until 3 weeks prior to the conference 25 %
 - Cancellation until 2 weeks prior to the conference 50 %
 - Cancellation within 2 weeks prior to the conference 100 %

CONCEPT HEIDELBERG reserves the right to change the materials, instructors, or speakers without notice or to cancel an event.

If the event must be cancelled, registrants will be notified as soon as possible and will receive a full refund of fees paid. CONCEPT HEIDELBERG will not be responsible for discount airfare penalties or other costs incurred due to a cancellation.

Terms of payment: Payable without deductions within 10 days after receipt of invoice.

Important: This is a binding registration and above fees are due in case of can-

cancellation or non-appearance. If you cannot take part, you have to inform us in writing. The cancellation fee will then be calculated according to the point of time at which we receive your message.

In case you do not appear at the event without having informed us, you will have to pay the full registration fee, even if you have not made the payment yet. Only after we have received your payment, you are entitled to participate in the conference (receipt of payment will not be confirmed!) (As of July 2022).

German law shall apply. Court of jurisdiction is Heidelberg.

Privacy Policy: By registering for this event, I accept the processing of my Personal Data. Concept Heidelberg will use my data for the processing of this order, for which I hereby declare to agree that my personal data is stored and processed. Concept Heidelberg will only send me information in relation with this order or similar ones. My personal data will not be disclosed to third parties (see also the privacy policy at www.gmp-compliance.org/eca_privacy.html). I note that I can ask for the modification, correction or deletion of my data at any time via the contact form on this website.



Date Live Online Training

Tuesday, 17 March 2026,
09.00 to approx. 17.00 h
Wednesday, 18 March 2026,
09.00 to approx. 16.30 h
All times mentioned are CET.

Technical Requirements

We use Webex for our live online training courses and webinars. At www.gmp-compliance.org/training/online-training-technical-information you will find all the information you need to participate in our events and you can check if your system meets the necessary requirements to participate. If the installation of browser extensions is not possible due to your rights in the IT system, please contact your IT department. Webex is a standard nowadays and the necessary installation is fast and easy.

Fees (per delegate, plus VAT)

ECA Members EUR 1,890
APIC Members EUR 1,990
Non-ECA Members EUR 2,090
EU GMP Inspectorates EUR 1,045
The conference fee is payable in advance after receipt of invoice.

Registration

Via the attached reservation form, by e-mail or by fax – **or search and register directly at www.gmp-compliance.org under the number 22205.**

Presentations/Certificate

The presentations will be made available to you prior to the Live Online Training as PDF files. After the event, you will automatically receive your certificate of participation.

Conference language

The official conference language will be English.

Organisation and Contact

ECA has entrusted Concept Heidelberg with the organisation of this event.

CONCEPT HEIDELBERG

P.O. Box 10 17 64
69007 Heidelberg, Germany
Phone +49(0)62 21/84 44-0
Fax +49(0)62 21/84 44 34
info@concept-heidelberg.de
www.concept-heidelberg.de

For questions regarding content please contact:

Dr Robert Eicher (Operations Director) at
+49(0)62 21/84 44 12 or per e-mail at
eicher@concept-heidelberg.de.

For questions regarding organisation please contact:

Ms Nicole Bach (Organisation Manager) at
+49(0)62 21/84 44 22, or at
nicole.bach@concept-heidelberg.de.